Enzon Pharmaceuticals, Inc. and Santaris Pharma have entered into a collaboration to develop and commercialize a series of RNA Antagonists based on Santaris Pharma’s LNA technology and utilizing Enzon’s oncology drug development expertise. Under the terms of the agreement, Enzon is licensing two of Santaris Pharma’s preclinical development compounds, the HIF-1 alpha antagonist (SPC2968) and the Survivin antagonist (SPC3042), and six additional proprietary RNA Antagonist ca...